A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021 on ClinicalTrials.gov · last registry update 2026-07-10
An unusually large phase 2: 230 participants, more than double the 114 typical for the stage. Due to report 12 July 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Number of gastrointestinal adverse events. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 230
- Started
- 2026-06-09
- Primary completion
- 2027-07-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of gastrointestinal adverse events
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.